Passions

Road cycling

Skiing

Experience

Abivax Announces $235.8 Million IPO

October 20, 2023

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Ryan Sansom
Partner, Boston
Denny Won
Partner, San Francisco
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Nyron J. Persaud
Partner, New York
Madhuri Roy
Partner, Palo Alto
Courtney Thorne
Partner, Boston
Elizabeth Anne Wright
Partner, Brussels
Xander Lee
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Stephanie Gentile
Partner, New York
Kevin King
Partner, Washington DC
Katie Kazem
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington DC
Rebecca Ross
Special Counsel, Washington DC
Randy Sabett
Special Counsel, Washington DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington DC
Karen Tsai
Special Counsel, Washington DC
Minkyu Park
Associate, New York
Jesse Schulman
Associate, Washington DC
Barry Kuang
Associate, Boston
Olivia Creser
Associate, New York
Peter A. Haddad
Associate, San Diego
Samuel Paullin
Associate, Chicago
Evan Leitner
Associate, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Cara Buchicchio
Associate, New York
Jason Valentine
Associate, Washington DC
Jessica Koffel
Associate, Brussels
Mor Agam
Associate, New York
Cathy Rude
Senior Paralegal, Boston

Related Practices & Industries

Exscientia – $510.4 Million IPO

October 6, 2021

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Read more

Related contacts

David Boles
Partner, London
Claire Keast-Butler
Partner, London
Div Gupta
Partner, New York
Marc Recht
Partner, Boston
David Wilson
Partner, London
Chris Stack
Partner, London
Dayne Brown
Associate, New York
Margaret D. Suh
Associate, New York
Meg Begur
Associate, London
Nicola Squire
Partner, London
Jack Jones
Associate, London
Charlotte Irvine
Associate, London
Tom Goodman
Partner, London
Paula Holland
Partner, London
Aaron Pomeroy
Partner, Colorado
Calvin Lee
Associate, New York
Ivor Elrifi
Partner, New York
Courtney Thorne
Partner, Boston

Related Practices & Industries

Exscientia Inks Investment of up to $525 Million

May 10, 2021

Cooley advised Exscientia, a clinical-stage pharmatech company, on its $225 million Series D funding round led by SoftBank Vision Fund 2, which is also providing an additional $300 million equity commitment that can be drawn at Exscientia’s discretion. Lawyers Claire Keast-Butler and Tom Goodman led the Cooley team advising Exscientia.

Read more

Related contacts

Claire Keast-Butler
Partner, London
Tom Goodman
Partner, London
Charlotte Irvine
Associate, London
Paula Holland
Partner, London
Marc Recht
Partner, Boston

Related Practices & Industries

Talaris Therapeutics – $150 Million IPO

May 6, 2021

Cooley advised the underwriters on Talaris Therapeutics' $150 million initial public offering of 8,825,000 shares of common stock. Morgan Stanley, SVB Leerink, Evercore Groupand Guggenheim Securitiesacted as joint book-running managers for the offering. Talaris Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol TALS, is a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation. Partners Richard Segal, Marc Recht and Div Gupta led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Marc Recht
Partner, Boston
Div Gupta
Partner, New York
Denny Xu
Associate, Boston

Related Practices & Industries

Celularity to Go Public Through SPAC Merger

January 14, 2021

Cooley advised Celularity, a clinical-stage biotechnology company developing off-the-shelf allogeneic therapies derived from the postpartum human placenta, on its agreement to become a public company by merging with GX Acquisition Corp., a special purpose acquisition company. Upon closing of the transaction, which is expected in Q2, GX will be renamed Celularity, and its common stock and warrants are anticipated to remain listed on Nasdaq under the new ticker symbols “CELU” and “CELUW.” Yvan-Claude Pierre, Marc Recht, Kevin Cooper and Marianne Sarrazin led the Cooley team advising Celularity on the transaction.

Read more

Related contacts

Kevin Cooper
Partner, New York
Yvan-Claude Pierre
Partner, New York
Marc Recht
Partner, Boston
Izzy Lubarsky
Associate, New York
DeVon Barnett
Associate, Washington DC
Megan Browdie
Partner, Washington DC
Bill Christiansen
Partner, Seattle
Jacqueline Grise
Partner, Washington DC
Rick Jantz
Associate, Los Angeles Santa Monica
Natasha Leskovsek
Of Counsel, Washington DC
Eileen Marshall
Partner, Washington DC
Phil Mitchell
Partner, New York
MaryBeth Shreiner
Associate, Reston
Zachary Sonenshine
Associate, New York
Geoffrey Spolyar
Partner, Boston

Related Practices & Industries

View more

Rankings & accolades

Chambers USA: Capital Markets – Massachusetts (2014 – 2023)

The Legal 500 US: Healthcare: Life Sciences (2013, 2016, 2020)

Who's Who Legal: Life Sciences (2017, 2018)

Super Lawyers: Rising Star (2007, 2010 – 2013)

Boston Business Journal: Biotech IPO (2015)


Excellent in all categories. Marc Recht is 'very technically skilled in corporate matters and plays a strong quarterback role.'

Legal 500